Form 8.1 - Covidien

DUBLIN, Ireland--()--Covidien:

FORM 8.1(a)&(b)(i)

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.1(a) AND (b)(i) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY OFFERORS, OFFEREES OR PARTIES ACTING IN CONCERT WITH THEM FOR THEMSELVES OR FOR DISCRETIONARY CLIENTS

1. KEY INFORMATION

     
Name of person dealing (Note 1)   Dennis H. Reilley
Company dealt in   Covidien plc

Class of relevant security to which the dealings being disclosed relate (Note 2)

  Ordinary Shares
Date of dealing   3 Dec 2014, 6 November 2014 and 19 August 2014

2. INTERESTS AND SHORT POSITIONS

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

         
    Long   Short
    Number   (%)   Number   (%)
(1) Relevant securities  

46,532

 

0.01%

   
(2) Derivatives (other than options)            
(3) Options and agreements to purchase/sell            
Total  

46,532

 

0.01%

   

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

         
Class of relevant security:   Long   Short
    Number   (%)   Number   (%)
(1) Relevant securities        

(2) Derivatives (other than options)

       

(3) Options and agreements to purchase/sell

       
Total        

3. DEALINGS (Note 4)

(a) Purchases and sales

         
Purchase/sale  

Number of relevant
securities

 

Price per unit (Note 5)

Sale   10,521   US$101.39
         

(b) Derivatives transactions (other than options transactions)

             

Product name,
e.g. CFD

 

Nature of transaction
(Note 6)

 

Number of relevant securities
(Note 7)

 

Price per unit
(Note 5)

             

(c) Options transactions in respect of existing relevant securities

(i) Writing, selling, purchasing or varying

                         

Product name,
e.g. call option

 

Writing, selling,
purchasing,
varying etc.

 

Number of securities
to which the option
relates (Note 7)

 

Exercise
price

 

Type, e.g.
American,
European etc.

 

Expiry
date

 

Option money
paid/received
per unit (Note 5)

                         

(ii) Exercising

         

Product name,
e.g. call option

 

Number of
securities

 

Exercise price per
unit (Note 5)

Option Exercise   10,521   US$39.32
         

(d) Other dealings (including transactions in respect of new securities) (Note 4)

         

Nature of transaction
(Note 8)

  Details  

Price per unit
(if applicable) (Note 5)

Credit of Dividend Equivalent Units

 

Credit of 9 dividend equivalent units pursuant to the terms of RSUs held.

 

N/A

 

Credit of Dividend Equivalent Units

 

Credit of 11 dividend equivalent units pursuant to the terms of RSUs held.

 

N/A

4. OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

None

 
 

Is a Supplemental Form 8 attached? (Note 9)

 

NO

Date of disclosure   5 December 2014
Contact name   Lisa Clemence
Telephone number   +1 508-452-4375

Name of offeree/offeror with which acting in concert

  Covidien plc

Specify category and nature of acting in concert status

  Director of Covidien plc

A person interested in 1% or more of any relevant securities in the Covidien plc (the “Company”) may have disclosure obligations under Rule 8.3 of the Irish Takeover Rules. This requirement will continue until the offer period ends.

The directors of the Company accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure that such is the case) the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.

Contacts

Covidien
Peter Lucht, 508-452-4168
Vice President
External Communications
peter.lucht@covidien.com
or
Lisa Clemence, 508-452-4375
Director
Corporate Communications
lisa.clemence@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com

Contacts

Covidien
Peter Lucht, 508-452-4168
Vice President
External Communications
peter.lucht@covidien.com
or
Lisa Clemence, 508-452-4375
Director
Corporate Communications
lisa.clemence@covidien.com
or
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com
or
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations
todd.carpenter@covidien.com